A systematic review of 27 human trials (3,811 participants) finds that nutritional interventions — led by calorie restriction (but including rapamycin, a caloric restriction mimetic) — reliably lower circulating inflammatory and secretory proteins linked to the senescence-associated secretory phenotype (SASP), while leaving the “core” markers of senescent cells themselves (p16, p21, telomere length) largely untouched. The authors argue this is a signal that diet modulates the noise senescent cells make, not necessarily their number , and that the field’s biomarkers are too crude to tell the difference.
For two decades, the promise has been seductive: eat right, and you might sweep away the “zombie” senescent cells that accumulate as we age and drive chronic disease. A new systematic review from the University Medical Center Groningen delivers a more sober verdict. Pooling 27 human interventional studies, the team asked a simple question — do nutritional strategies actually shift the biological markers of cellular senescence in people?
The answer is a qualified “partly.” The most consistent effect, seen across calorie restriction, rapamycin, metformin, omega-3 fatty acids, and some plant compounds, was a reduction in circulating inflammatory and secretory proteins — the interleukins, matrix metalloproteinases, and related factors that make up the SASP. Calorie restriction was the standout, reproducibly lowering these markers and suppressing a validated senescence gene signature (SenMayo) in fat tissue across multiple trials.
But here is the twist that matters. The classical, more specific markers of senescent cells — the cell-cycle brakes p16 and p21, and telomere length — barely moved, or moved unpredictably. In the landmark CALERIE trial, two years of roughly 12% calorie restriction cut SASP proteins and a fat-tissue senescence signature, yet did not budge p16 or p21. Telomere length showed no net change at all, even as DNA-methylation “clocks” registered slower aging.
The authors’ interpretation is deliberately deflationary: because SASP proteins are heterogeneous and not unique to senescent cells, a drop in them may simply reflect a general anti-inflammatory, metabolic benefit — not a reduction in senescent-cell burden. In people losing weight or reversing prediabetes, that confound is severe.
The bigger message is methodological. The review found that only one of the included trials was rated low risk of bias, and that studies rarely used the same markers, making comparison nearly impossible.
The broader review lands on a sober verdict that applies squarely to rapamycin: nutritional and mimetic interventions reliably move inflammatory SASP markers, but leave the more specific senescence markers — and any proof of reduced senescent-cell burden — largely untouched.
Actionable Insights
For rapamycin specifically, the honest read is: the drug is best supported as a senomorphic (SASP suppressor), not a senolytic. The strongest human signal — reduced p16, TNF-α, IL-6 in breast tissue at 2 mg/day for 5–7 days (Bouamar 2023) — came bundled with increased p21 and reduced Ki-67, i.e. growth arrest, plus a high risk-of-bias rating and a cancer-tissue confound. A 12-week low-dose pilot (0.5–2 mg/day, serum <6 ng/mL; Singh 2016, N=13) and a kidney-transplant study (Chebel 2016, N=17) were both uncontrolled. No formal effect sizes are computable — this was a narrative review with no meta-analysis.
Three practical caveats. First, every human rapamycin trial here used continuous daily dosing; the intermittent weekly regimens (roughly 5–8 mg once weekly) common in longevity practice were not tested against senescence endpoints at all, so this evidence does not validate that paradigm. Second, the anti-senescence effect is inseparable from generic anti-inflammatory/immunosuppressive action.
Context / Source
- Open Access Paper: Effects of nutritional interventions (and calorie restriction mimetics) on biomarkers of cellular senescence in humans: a systematic review
- Authors / Institution: Yao Lin, Abdullah Altulea, Marco Demaria — European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen (UMCG), The Netherlands. (Demaria is a well-known senescence/SASP biologist, which lends domain credibility.)
- Journal: Ageing Research Reviews (Elsevier)
- Impact evaluation: The impact score of this journal is 15.5 (2025 JCR Journal Impact Factor, released June 2026; CiteScore 14.2; Q1, ranked ~19/207 in category),therefore this is a High impact journal.